Intarcia Therapeutics has announced a $225 million investment which will go largely to pay for a planned trial of its once-a-year ITCA 650 pump and drug combination device aimed at revolutionizing the market for type 2 diabetes, establishing it as the standard of care.
The undisclosed investors in the Boston-based company will get 1.5 percent of future global net sales of the device, with the option to convert that royalty into Intarcia common stock at a $5.5 billion company valuation during an agreed-upon conversion period. Morgan Stanley acted as the agent for the deal.
Including this investment, the company has now raised more than $1 billion in financing in the last five years, with more expected in coming years in milestone payments.
“This large and innovative financing announced today is another first-of-its-kind in our industry, and it shows investor confidence in our pivotal data, our partnerships and our overall approach to a huge unmet need and opportunity in type 2 diabetes,” said Intarcia CEO Kurt Graves in a statement.
More on this story here.
Eddie
No comments:
Post a Comment
The lowcarb team value your comments. Thank you for taking the time to contribute to our blog. Please note! negative comments and insults from anonymous idiots, with nothing to add to the debate will not be authorised. However, we welcome constructive criticism.
The best of health to you and yours.
Eddie